These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 19692786)

  • 1. [Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
    Fukushima T; Iwao H; Nakajima A; Miki M; Sakai T; Sawaki T; Tanaka M; Masaki Y; Hirose Y; Umehara H
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1387-9. PubMed ID: 19692786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
    Fukushima T; Nakamura T; Iwao H; Nakajima A; Miki M; Sato T; Sakai T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Nakajima H; Motoo Y; Umehara H
    Anticancer Res; 2011 Jun; 31(6):2297-302. PubMed ID: 21737655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
    Yuan ZG; Jin J; Huang XJ; Li Y; Chen WM; Liu ZG; Chen XQ; Shen ZX; Hou J
    Chin Med J (Engl); 2011 Oct; 124(19):2969-74. PubMed ID: 22040537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
    Bao L; Lu XJ; Zhang XH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma].
    Yuan ZG; Hou J; Zhou F; Fu WJ; Chen YB; Xi H; Yang SL
    Zhonghua Xue Ye Xue Za Zhi; 2006 Oct; 27(10):653-5. PubMed ID: 17343194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
    Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
    Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
    J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
    Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
    Jagannath S; Barlogie B; Berenson JR; Siegel DS; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Esseltine DL; Anderson KC
    Br J Haematol; 2008 Nov; 143(4):537-40. PubMed ID: 18783399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
    Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD
    Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
    Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC
    J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
    Li J; Zhao Y; Luo SK; Huang BH; Ding Y; Tong XZ; Wang HH; Zheng D; Su C; Peng AH
    Ai Zheng; 2008 Apr; 27(4):429-34. PubMed ID: 18423132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
    Corso A; Varettoni M; Mangiacavalli S; Zappasodi P; Pica GM; Algarotti A; Pascutto C; Lazzarino M
    Eur J Haematol; 2009 Nov; 83(5):449-54. PubMed ID: 19519727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
    Ikeda H; Hayashi T; Nojima M; Yasui H; Ikeda Y; Ishida T; Adachi M; Imai K
    Rinsho Ketsueki; 2005 Apr; 46(4):269-73. PubMed ID: 16444959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
    Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; San Miguel JF; Cavenagh JD; Anderson KC
    Br J Haematol; 2007 Jun; 137(5):429-35. PubMed ID: 17451408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
    Sood R; Carloss H; Kerr R; Lopez J; Lee M; Druck M; Walters IB; Noga SJ
    Am J Hematol; 2009 Oct; 84(10):657-60. PubMed ID: 19731393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
    Chim CS
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):181-2. PubMed ID: 17846773
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.